3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
15
Waldenstrom Macroglobulinemia
1
Recurrence
1
Neoplasm, Residual
1
Myasthenia Gravis
1
Leukemia, Plasma Cell
1
Infections
1
Immunoglobulin Light-chain Amyloidosis
1
Cytokine Release Syndrome
1
Interventions
Dexamethasone
38
Melphalan
20
Bortezomib
18
Cyclophosphamide
17
Calcium Dobesilate
14
Filgrastim
13
daratumumab
11
Peripheral Blood Stem Cell Transplantation
10
pomalidomide
9
Lenalidomide
8
fludarabine phosphate
7
dexamethasone acetate
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
Granulocyte Colony-Stimulating Factor
5
Cyclosporine
5
venetoclax
4
ixazomib
4
dexamethasone 21-phosphate
4
Thalidomide
4
Etoposide
4
Busulfan
4
auricularum
3
Tacrolimus
3
Radiotherapy
3
Focal Adhesion Protein-Tyrosine Kinases
3
Epoetin Alfa
3
Doxycycline
3
Darbepoetin alfa
3
Thiotepa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immunoglobulin Light-chain Amyloidosis
×
talquetamab
×
Clear all
NCT06855121
2025-03-03
NIMMS
St. Olavs Hospital
Recruiting
400 enrolled